• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medicine. >Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
【24h】

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma

机译：预灌注患者的表皮生长因子受体 - 突变或促进淋巴瘤激酶 - 漂移肺腺癌患者预处理患者的疗效和安全性和其配体抑制剂的疗效和安全性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immune-checkpoint inhibitor (ICI) efficacy in patients with non-small cell lung cancer (NSCLC) harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI efficacy against epidermal growth-factor receptor ( EGFR ) / anaplastic lymphoma kinase ( ALK ) / c-ros oncogene 1 ( ROS1 )-mutated NSCLC patients in the real-world setting. In this retrospective, multicenter study on adults with ICI-treated EGFR- mutated or ALK- or ROS1 -translated NSCLCs, we analyzed clinical characteristics and outcomes: ICI-treatment duration, and progression-free survival (PFS), objective response rate, duration of response, and overall survival (OS) from immunotherapy initiation. Fifty-one NSCLC patients (mean age, 58.0 years) were included from 20 French centers: 61% were never-smokers and 59% were women. Among them, 82% had EGFR -activating mutations, 16% ALK translocations, or 2% ROS1 translocations. Before ICI therapy, patients had received a median of 3 treatment lines (including tyrosine-kinase inhibitor). The median PFS was 2.1 (95% confidence interval [CI], 1.5–3.2) months for the entire cohort, 2.2 (95% CI, 1.4–3.2) for EGFR -mutated patients, and 2.4 (95% CI, 2.1–not reached) months for ALK -translocated patients. The median OS was 14.7 (95% CI, 12.1–19.2) months for the entire population and 13.9 (95% CI, 8.8–20.0) and 19.2 (95% CI, 13.1–not reached) months for EGFR -mutated and ALK -translocated patients, respectively. Seven (13.7%) patients were treated with ICI for 9 months. Toxicities were reported in 22% (11/51), including 8% (4/51) grade ≥3. In this real-world setting, analysis of ICI PFS against EGFR -mutated or ALK -translocated NSCLC patients appeared close to that observed in pretreated unselected NSCLC patients. The more promising OS probably linked to post-ICI treatments. Large prospective studies on these patient subsets are needed.
机译：患有分子改变的非小细胞肺癌（NSCLC）患者的免疫检查点抑制剂（ICI）疗效仍然仍然令人难以释放。本研究旨在确定针对表皮生长因子受体（EGFR）/ Anaplastic淋巴瘤激酶（ALK）/ C-ROS癌基因1（ROS1）的疗效在真实世界中的疗效。在这种回顾性中，对ICI治疗的EGFR-突变或ALK或ROS1-翻译的NSCLC的多中心研究，我们分析了临床特征和结果：ICI治疗持续时间，无进展生存（PFS），客观反应率，持续时间免疫疗法启动的反应和整体存活（OS）。五十一类NSCLC患者（平均年龄，58.0岁）包括在20个法国中心：61％的人永远不会吸烟，59％是女性。其中，82％具有EGFR-活化的突变，16％ALK易位或2％ROS1易位。在ICI治疗之前，患者接受了3条治疗系（包括酪氨酸激酶抑制剂）的中位数。中位数PFS为整个队列的2.1（95％置信区间[CI]，1.5-3.2）个月，2.2（95％CI，1.4-3.2），用于EGFR - 审计患者，2.4（95％CI，2.1 - 不达到了脯氨酸患者的月份。整个人口中位OS为14.7（95％CI，12.1-19.2）个月，13.9（95％CI，8.8-20.0）和19.2（95％CI，13.1 - 未达到）月，适用于EGFR - 估算和ALK - 分析患者分别。七（13.7％）患者用ICI治疗> 9个月。报告毒性22％（11/51），其中包括8％（4/51）级≥3。在这种真实世界的环境中，对EGFR的ICI PFS对EGFR的分析或ALK -RANSCORCATED NSCLC患者的分析似乎在预处理未选择的NSCLC患者中观察到。越有前途的操作系统可能与后ICI治疗相关联。需要对这些患者亚群的大型前瞻性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号